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Analysis of the mitochondrial proteome would provide valuable insight into the function of this important organelle, which 
plays key roles in energy metabolism, apoptosis, free radical production, thermogenesis, and calcium signaling. It could also 
increase our understanding about the mechanisms that promote mitochondrial disease. To identify proteins that are antigeni-
cally dominant in human liver mitochondria, we generated >240 hybridoma cell lines from native mitochondrial proteins after 
cell fusion, screening, and cloning. Antibodies that recognized mitochondrial proteins were identified by screening human liver 
cDNA expression libraries. In this study, we identified 6 major antigens that were recognized by at least 2 different mono-
clonal antibodies (mAbs). The proteins that were antigenically dominant were: acetyl-Coenzyme A acyltransferase 2 (mito-
chondrial 3-oxoacyl-Coenzyme A thiolase), aldehyde dehydrogenase 1 family member A1, carbamoyl phosphate synthetase 1, 
dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex), enoyl coenzyme A hydratase 1, 
and hydroxysteroid (11-beta) dehydrogenase 1. We also determined the subcellular localizations of these enzymes within the 
mitochondria using immunohistocytochemistry. We believe that these well-characterized antibodies will provide a valuable 
resource for the Human Liver Proteome Project (HLPP), and will make studies aimed at investigating liver mitochondrial 
function far easier to perform in future. Our results provide strong evidence that, (i) depletion of dominant proteins from liver 
mitochondrial samples is possible and, (ii) the approaches adopted in this study can be used to explore or validate pro-
tein-protein interactions in this important organelle. 
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The mitochondrion is a highly specialized subcellular or-
ganelle. Mitochondria play many crucial and diverse roles 
that affect normal cellular processes as well as disease pa-
thology. Mitochondria not only supply ATP to the cell, but 
also play roles in redox cell signaling [1–3], apoptotic cell 
signaling [4], and cellular homeostasis. Mitochondrial dys-
function is known to contribute to several human diseases, 
such as diabetes, cancer, neurodegeneration, and cardio-
vascular pathology [5–12]. Specifically, the accumulated 
damage caused by reactive oxygen and nitrogen species, 
together with binding of environmental toxins are known to 
contribute to the development of the more prevalent neu-
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rodegenerative disorders. These include Parkinson’s, Alz-
heimer’s, and Huntington’s diseases, amyotrophic lateral 
sclerosis, Down’s syndrome, and schizophrenia, as well as 
the aging process itself [13–25]. Mitochondria can also be 
adversely affected by cancer treatment and some chemicals 
have been shown to induce mitochondrial-mediated apop-
tosis in human cancer cells [26]. Because proteins execute 
mitochondrial function, researchers have traditionally paid 
more attention to changes in mitochondrial protein structure 
and function than studying mitochondrial DNA mutation in 
disease pathology. The identification and analysis of the 
mitochondrial proteome should, therefore, provide better 
understanding of the numerous functions of this important 
organelle and elucidate the mechanisms underlying mito-
chondrion-related diseases. Monoclonal antibodies (mAbs), 
with their inherently high specificities and sensitivities, are 
powerful tools in biological research. Antibody-based tech-
nologies (including antibody microarrays) make it possible 
to detect and quantitate protein expression levels in mito-
chondria. Furthermore, isolation of mitochondrial oxidative 
complexes can now be achieved using mitochondrial pro-
tein-specific antibodies [27]. To keep pace with the capa-
bilities of the new proteomics technologies will require ac-
cess to a large number of well characterized antibodies.  
In earlier studies, the proteins that induce T-cell re-
sponses resulting in antibody generation were classified as 
antigenically dominant proteins. Identification and charac-
terization of immunodominant proteins or immunodominant 
epitopes in protein mixtures is one of the most important 
issues in vaccine design and monoclonal antibody genera-
tion. It has been demonstrated that immunodominance, in-
volving a B lymphocyte response, is usually limited to a 
small proportion of the potential determinants of a protein 
antigen [27]. Several aspects that appear to be involved in 
immunodominance have been investigated, such as proc-
essing of the antigen, peptide competition for class II pres-
entation, and T-cell recognition of immunodominant epi-
topes, for example [28,29]. 
In this paper we generated a hybridoma bank by immu-
nizing mice with isolated mitochondria, and fractionated 
mitochondrial protein mixtures which contained numerous 
proteins. In an earlier paper, we described the approaches 
taken to identify mAb specificity, using mass spectrometry 
and cDNA expression library screening [30]. Using these 
approaches, in this study, we identified 19 target proteins 
that were recognized by 244 hybridoma supernatants. 
Among these target proteins, six proteins were recognized 
by two or more hybridomas. We defined these six proteins 
as antigenically dominant proteins, because of their strong 
ability to induce antibody responses in immunized mice. 
These results enabled us to test the mAbs for their ability to 
deplete the recognized protein from liver tissue lysates. The 
results of these studies will guide future research aimed at 
generating monoclonal antibodies against the less immu-
nodominant proteins within liver tissue. 
1  Materials and methods 
1.1  Chemicals and liver tissue samples  
Unless otherwise indicated, all biochemicals were pur-
chased from Sigma (St. Louis, MO, USA) or Bio-Rad 
(Hercules, CA, USA). 
1.2  Isolation of human liver mitochondria  
Mitochondria were isolated according to standard centrifu-
gation procedures with minor adaption [1]. Ten grams of 
human liver tissue was homogenized in 40 mL of a buffer 
containing 50 mmol L−1 sucrose, 10 mmol L−1 HEPES, 1 
mmol L−1 EDTA, 200 mmol L−1 Mannitol and protease in-
hibitors (Pierce, Chicago, IL, USA), pH 7.4 at 4°C. After 
centrifugation at 1000×g per homogenized liver, mitochon-
dria were collected by centrifugation of the supernatant at 
10000×g for 10 min at 4°C. Mitochondria were re-sus-      
pended in isotonic buffer comprising 10 mmol L−1 Tris-HCl 
pH 7.8, 0.25 mol L−1 sucrose, 0.2 mmol L−1 EDTA and 0.5 
mmol L−1 PMSF. Protein concentration was calculated us-
ing BCA-reagent (Pierce, Chicago, IL, USA) against a 
standard curve constructed using BSA. For animal immuni-
zation and mAb characterization, aliquots of 5 mg mito-
chondria were centrifuged at 14000×g for 10 min at 4°C 
and the supernatants discarded. The pellets were used for 
immunization or frozen in liquid N2 and stored at −80°C for 
up to 1 month. 
1.3  Preparation of mitochondrial proteins 
1.3.1  Preparation of mitochondrial total lysates 
Mitochondria were re-suspended in 100 μL isotonic buffer 
and 300 μL of RIPA (1% NP-40, 0.15 mol L−1 sodium chlo-
ride, 2 mmol L−1 EDTA, 50 mmol L−1 sodium fluoride, 0.2 
mmol L−1 sodium orthovanadate, 0.01 mol L−1 sodium 
phosphate, and protease inhibitors pH 7.6) added and the 
solution incubated on ice for 30 min. Mitochondrial proteins 
were obtained by recovery of the RIPA lysate supernatant 
after centrifugation at 14000×g for 30 min at 4°C. Up to 8 
mg of mitochondrial proteins could be prepared from 1 g of 
liver tissue using this method. 
1.3.2  Preparation of fractionated mitochondrial proteins 
Mitochondrial proteins were fractionated into 8 fractions 
according to their molecular weight, as determined by 
SDS-PAGE. The molecular weight ranges of the 8 fractions 
obtained were; fraction 1 (≥100 kD), fraction 2 (75–100 kD), 
fraction 3 (62–75 kD), fraction 4 (50–62 kD), fraction 5 
(43–50 kD), fraction 6 (37–43 kD), fraction 7 (25–37 kD), 
fraction 8 (≤25 kD). The fractionated mitochondrial proteins 
were recovered from SDS-PAGE gels in positions corre-
sponding to their expected MW, and electro-eluted using 
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Electro-Eluter (Bio-Rad Model 422).  
1.4  Generation and characterization of mAbs against 
human liver mitochondrial proteins 
Mice were immunized with 0.5–1.0 mg of mitochondrial 
proteins or with isolated mitochondria particles containing 
equivalent amounts of the proteins. Individual mice were 
immunized with 100–200 μg of the 8 fractionated mitochon-
drial proteins. Hybridoma cells were generated following 
standard cell fusion and cloning procedures. Monoclonal an-
tibodies (mAbs) were characterized by determining their an-
tibody isotype, and their specificities towards mitochondrial 
proteins identified using ELISA and Western blot techniques. 
1.5  Identification of mAb specificity using cDNA 
expression library screening  
To determine the specific antigen recognized by each 
monoclonal antibody produced in this study, a λ expression 
Uni-ZAPâ XR pre-made liver cDNA library (Stratagene, La 
Jolla, CA, USA) was screened with selected hybridoma 
supernatants. The screening and identification procedure 
were performed in accordance with the manufacturer’s in-
structions. Briefly, the cDNA library was plated onto 150 
mm plates at 5×104 pfu/plate and nitrocellulose membranes 
impregnated with 10 mmol L−1 IPTG were used to induce 
cDNA expression and subsequent transfer of the proteins. 
Washed membranes were blocked overnight in TBST con-
taining 1% skimmed milk at 4°C, and then incubated with 
primary antibody (hybridoma supernatant in blocking buffer 
diluted at 1:5–1:100) for 2 h at 37°C. Bound antibodies 
were detected using horse radish peroxidase (HRP)-conju-     
gated goat anti-mouse IgG with the ECL detection system 
(Amersham Pharmacia Biotech). The plaques corresponding 
to each positive spot on the film were cored, and the phage 
particles released into TBS buffer. To verify a positive 
clone, a second round of membrane screening was per-
formed by plating the released phage pool onto 150 mm 
plates at a density of 1×103–3×103 pfu/plate, following the 
same procedure as for the primary screening. At such low 
plating densities, individual positive clones could be readily 
isolated from the plates. The inserted cDNA sequences from 
the positive phages were transferred into a pBluescript 
phagemid (pBluescript SK+) for sequencing after in vivo 
excision following the manufacturer’s instructions. A 
BLAST was used to interrogate the sequencing data (Gen-
Bank). Because the inserted cDNA in pBluescript SK+ can 
be induced to express recombinant protein in Escherichia 
coli, SDS-PAGE and western blots were used to validate 
antigen expression and antigen-antibody reactions. The E. 
coli SOLR strain containing pBluescript SK+ were induced 
using 1 mmol L−1 IPTG for 3 h at 30°C when cultures 
reached an A600 of 0.3. Bacterial proteins were loaded onto 
SDS-PAGE gels and western blotted. The SOLR strain 
containing an empty vector, pBluescript SK−, was used as a 
negative control. 
1.6  Immunohistochemistry and immunofluorescence 
staining  
To assess whether the mAbs produced in this study could 
recognize the mitochondria within liver cells, immunohis-
tochemistry staining of liver tissues and immunofluorescent 
staining of liver carcinoma cells were performed. Frozen 
sections were fixed in dimethyl ketone for ten min at 4°C. 
After washing in TBST for 5 min, slides were incubated for 
30 min in 3% hydrogen peroxide in methanol at room tem-
perature to quench any endogenous peroxidase activity. 
After washing 3 times with TBST, the slides were blocked 
for 30 min with normal goat serum at room temperature. 
Primary antibodies were applied to the blocked sections and 
incubated overnight at 4°C. Positive signals were visualized 
using diaminobenzidine tetrahydrochloride (DAB) solution, 
after a 20 min incubation of the slides at 37°C with 
HRP-labeled goat anti-mouse IgG antibody (GBI, Beijing, 
China). Slides were counter-stained with hematoxylin for 5 
min and washed in deionized H2O for 1 min. 
Rhodamine 123 (green) was used to visualize mitochon-
dria in live liver carcinoma cell preparations (Huh7) and 
mAb binding detected using TRITC-conjugated AffiniPure 
Goat Anti-Mouse IgG (H+L) (red) for double staining. 
Monolayer cells were cultured in RPMI 1640 containing 1 
µg mL−1 Rhodamine 123 for 30 min at 37°C, and the cells 
fixed in TBS containing 4% paraformaldehyde and 0.2% 
Triton-100 for 20 min at 4°C. Fixed cells were washed 3 
times with PBS and incubated with primary antibodies 
overnight at 4°C. Cells were incubated with the secondary 
antibody for 30 min at 37°C. After washing 3 times, the 
slides were analyzed using fluorescence microscopy (Olym-
pus, Tokyo, Japan). 
1.7  Depletion of antigenically dominant proteins from 
human liver mitochondria protein extracts 
Purified mAb BAH103 (100 µg) was incubated with 100 μL 
Protein G agarose suspension (Pierce) overnight at 4°C in a 
total of 600 μL PBS buffer. After washing 3 times with PBS, 
1 mg of the mitochondrial proteins were added to the mAb-      
ProteinG-agarose mix and incubated at 4°C for 3 h. Proteins 
that did not bind mAbs were loaded onto SDS-PAGE gels 
and western blotted. Proteins that did not bind mAbs were 
used to immunize mice to generate anti-sera. 
2  Results and discussion 
2.1  Isolation of human liver mitochondrial proteins 
Mitochondria are one of the most important organelles for 
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the maintenance of cell life. Given the contribution of mi-
tochondria to the normal physiology and pathology of the 
cell, it is not surprising that this organelle contains around 
1200 proteins. Although the exact number of mitochondrial 
proteins in mammals is not known, about 600–700 have 
been characterized [31]. In this study we used homogeniza-
tion and standard differential centrifugation techniques to 
isolate mitochondria from human liver tissue, and isolated 
48 mg of mitochondrial protein from 10 g of liver. The iso-
lated mitochondria were lysed, and the total mitochondrial 
protein content analyzed using 1D and 2D-PAGE [30], and 
succinate dehydrogenase activity testing (data not shown). 
This confirmed the purity and enrichment of the mitochon-
drial protein in the samples. Using PDQuest software (Ver 
7.0, Bio-Rad) the MW and isoelectric point (pI) of each spot 
were analyzed. This revealed that the MW and pI for most 
of the proteins ranged between 20 and 80 kD and pH 3–8. 
These data are consistent with those obtained in previous 
studies of mitochondrial proteomes [3]. The MW of the 
most abundant proteins ranged between 30 and 80 kD (as 
determined by 1D and 2D-PAGE). Fractionated mitochon-
drial proteins were analyzed using SDS-PAGE (Figure 1A). 
The sera of the mice immunized with the fractionated mi-
tochondrial proteins were analyzed by Western blot (Figure 
1B).  
2.2  Generation and characterization of mAb hybri-
doma cell lines 
Antibodies, especially mAbs, are one of the most powerful 
tools in contemporary biological research. Analysis of cell 
or tissue protein profiles using antibody microarray tech-
nology, however, requires access to large quantities of 
well-characterized antibodies [4]. To establish a platform 
for large scale antibody production, we raised hybridoma 
cell lines from BALB/c mice immunized with mitochon-
drial protein mixtures isolated from human liver prepara-
tions. All of the 244 monoclonal hybridomas we established 
were tested for their isotypes. Isotype testing revealed that 
89.8% were IgG1, 3.2% were IgG2a, and 4.9% were IgG2b 
(Table 1). These mAbs were further characterized by west-
ern blotting using the hybridoma supernatants. The data for 
some of these experiments are shown in Figure 2. Most 
mAbs recognized antigens located within mitochondria in 
the liver tissue sections and the mAbs reacted positively 




Figure 1  SDS-PAGE and Western blot analysis of fractionated mitochondrial proteins. Total mitochondrial proteins were separated on SDS-PAGE gels 
and electro-eluted into 8 fractions according to their molecular weights. A, Lanes 1–8: Coomassie blue stained SDS-PAGE gel showing the 8 protein frac-
tions migrating according to their expected MWs. B, Lanes 1–8: Western blot analysis of the same fractionated proteins, illustrating the antibody staining 
patterns obtained using sera from mice immunized with each of the different fractions. 
Table 1  mAbs against human liver mitochondria obtained by immunization with fractionated proteins 
Class and subclass 
Immunogen 





IgG2a IgG2b IgG3 IgM 
Mitochondria 3 20 14 5 1 0 0 
Mitochondrial proteins 3 23 17 1 5 0 0 
Fractionated mitochondrial proteins 14 201 188 3 6 2 2 
Total 20 244 219 (89.8%) 9 (3.7%) 12 (4.9%) 2 (0.8%) 2 (0.8%) 
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Figure 2  Mitochondrial proteins were blotted against different mAbs (i.e., 
hybridoma supernatants) under reduced conditions. Different mAbs pat-
terns can be seen in Western blots of human liver mitochondrial proteins. 
The antigens which were recognized by the mAbs were: ALDH1A1 (lane 
1), ACAA2 (lane 2), CPS1 (lane 3), DLAT (lane 4), HSD11B1 (lane 5)  
and ECH1 (lane 6). 
terns observed on western blots (Figure 2). 
2.3  Antigen identification using a human liver cDNA 
expression library 
Many methods have been developed to detect antigens pro-
duced by individual bacterial colonies or phage plaques; 
these recombinant proteins can be identified using a primary 
antibody against the protein of interest. Alternatively, isola-
tion of full length or partial protein-encoding genes from 
large recombinant cDNA libraries can also be achieved us-
ing antibodies. Such coding sequences can be used for large 
scale recombinant protein expression to facilitate functional 
and structural analyses of protein antigens. 
In this study, 129 mAbs raised against human liver mi-
tochondrial proteins were detected using a human liver 
cDNA expression library to determine the specificities of  
the mAbs. We identified 78 mAbs that were specific for 10 
different protein types. Six of these proteins could be classi-
fied as antigenically dominant (Tables 2 and 3) and at least 
2 hybridoma cell lines could be produced for each of the six 
proteins. Table 2 shows the 30 hybridoma cell lines that 
recognize carbamoyl phosphate synthetase 1 (CPS1). The 
hybridoma cell lines were obtained from mice immunized 
with fractionated or total mitochondrial protein preparations. 
These results show that CPS1 is the dominant protein anti-
gen within mitochondria. CPS1 is believed to be one of the 
most abundant proteins in the liver, comprising approxi-
mately 4% of the total protein content of this organ [32,33]. 
It is possible, therefore, that relatively high levels of this 
protein in the mitochondria could influence immune re-
sponses, as has been suggested previously where it was 
found that antigen priming was dose dependent [34].  
In protein mixtures, we found that some, but not all of 
the most abundant proteins were antigenic, whilst some, but 
not all of the antigenic proteins were abundant. We also 
found that the number of hybridoma cell lines derived from 
mice immunized with the fractioned mitochondria proteins 
was greater than the number of hybridoma cell lines derived 
from mice immunized with the mitochondria protein ex-
tracts. This could indicate that the six proteins identified are 
antigenically dominant proteins within mixtures (across a 
range of different molecular weights) (Tables 2 and 3). The 
six proteins were more antigenic in the fractioned mito-
chondria preparations compared to the unfractionated mate-
rial. This could be because the representation of the mito-
chondrial proteins in the fractioned sample was less than 
that of the unfractionated samples; however, each individual 
protein present in the fractionated samples will be present in 
greater quantity. Thus, following fractionation, proteins that 
were not found to be strongly antigenic in the unfraction- 
ated material became immunodominant. Supporting this 
hypothesis, the hybridoma Acetyl-Coenzyme A acyltrans- 




Number of hybridomas Immunogen 
1 Mitochondrial proteins 
24 
Fractionated mitochondrial proteins 
(50–62 kD) 
ALDH1A1 Aldehyde dehydrogenase 1 family, 
member A1 
57 94 44 
19 
Fractionated mitochondrial proteins 
(43–50 kD) 
3 Mitochondrial proteins 
CPS1 Carbamyl phosphate synthetase 1 164 95 30 
27 
Fractionated mitochondrial proteins 
(≥100 kD) 
1 Mitochondrial proteins DLAT Dihydrolipoamide S-acetyltransferase  
(E2 component of pyruvate dehydrogenase com-
plex) 
70  6 
5 
Fractionated mitochondrial proteins 
(62–75 kD) 
2 Mitochondrial proteins HSD11B1 hydroxysteroid (11-beta) dehydro-
genase 1 
32 78 4 
2 Mitochondria 
ACAA2 Acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
42 87 3 3 
Fractionated mitochondrial proteins 
(37–43 kD) 
ECH1 Enoyl Coenzyme A hydratase 1 36 71 2 2 Mitochondrial proteins 
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Table 3  Anti-mitochondria protein mAbs identified by cDNA expression library screening 
Antigen Hybridoma 
Number of positive 
clones/sequenced clones 
cDNA expressed protein/Full 
length of Protein sequence (aa) 
ALDH1A1 Aldehyde dehydrogenase 1 family, member A1 CGG06 2/4 501 (1–501)/501 
ACAA2 Acetyl-Coenzyme A acyltransferase 2 (mitochon-
drial 3-oxoacyl-Coenzyme A thiolase) 
CCD031 2/4 397 (1–397)/397 
CPS1 Carbamyl phosphate synthetase 1 BEH045 3/6 1227 (274–1500)/1500 
DLAT Dihydrolipoamide S-acetyltransferase (E2 compo-
nent of pyruvate dehydrogenase complex) 
AEB018 5/6 427 (221–647)/647 
HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1) CBF245 3/6 292 (1–292)/292 
ECH1 Enoyl Coenzyme A hydratase 1 BAH103 3/8 325 (4–325)/328 
 
ferase 2 (mitochondrial 3-oxoacyl-Coenzyme A thiolase) 
(ACAA2) cell lines were only obtained from mice immu-
nized with fractioned mitochondria proteins. These findings 
indicate that protein fractionation may be a good method for 
producing mAbs. In addition, western blot analysis of the 
bacteria proteins expressed from all the positive clones fur-
ther demonstrates that recombinant proteins expressed by 
positive clones can be recognized by the corresponding hy-
bridoma cell culture supernatants, at their expected MWs 
(Figure 3).  
The mAb identification success rate using this approach 
was around 50%; this rate might be related to factors such 
as the capacity of the cDNA library and the length of the 
inserted sequences. Because the average length of the in-
serts was 1.6 kb in the cDNA library used in this study, only 
partial sequences of the genes encoding proteins with large 
MWs were probably present in the phage library (Table 3). 
Furthermore, negative results will be obtained when the 
epitopes recognized by the mAbs are not located within the 
peptide expressed by the phage library. Positive clones will 
not be obtained either, if the mAbs recognize epitopes 
within a protein that require posttranslational modifications. 
Therefore, it is not possible to identify all mAbs using 
cDNA expression libraries. 
In the newly published database ‘Liverbase’, 6789 hu- 
man liver proteins were identified by mass spectrometry  
 
 
Figure 3  Characterization of mAb specificity using cDNA expression 
library screening. A human liver cDNA expression library was plated and 
the recombinant proteins expressed were transferred onto nitro cellulose 
membranes following induction with IPTG (Materials and methods). A, 
The cDNA sequences of positive plaques (red circles) recognized by mAb 
BGB095 in the Western blot were determined. The identity of the antigen 
was determined by BLAST analysis of GenBank. The 36 kD protein rec-
ognized by mAb BGB095 was identified as ECH1. B, To confirm this, the 
expressed proteins were subjected to Western blot and SDS-PAGE analysis. 
The smaller antibody positive bands with MWs less that 36 kD 
may be ECH1 degradation products (lane 6). 
that contained 2–117 unique peptides. All of the six proteins 
identified by the mAbs in this study are included (http://    
liverbase.hupo.org.cn/liverbase/) in this database. The 
number of unique peptides for each protein could be an in-
dicator of the abundance of a protein in the liver. Aldehyde 
dehydrogenase 1 family member A1 (ALDH1A1) was 
listed as protein number 3339 in the database. Only three 
unique peptides are associated with it in the database (the 
lowest number of unique peptides of all the six antigenically 
dominant proteins). We generated forty four hybridoma cell 
lines for ALDH1A1 in the present studies (the highest 
number of hybridoma cell lines for the six antigenically 
dominant proteins). Acetyl-Coenzyme A acyltransferase 2 
(mitochondrial 3-oxoacyl-Coenzyme A thiolase (ACAA2) 
(protein number 59) was shown to contain thirty eight 
unique peptides (the highest number of unique peptides of 
the six antigenically dominant proteins). We generated only 
three hybridoma cell lines for ACAA2 in our study (close to 
the lowest number of hybridoma cell lines for the six anti-
genically dominant proteins). We believe that identification 
of the six antigenically dominant proteins recognized by our 
mAbs was not only affected by their relative abundance in 
the liver (or number of unique peptides), but also by anti-
genic and/or other factors such as amino acid sequence ho-
mology between the murine and human orthologues. Previ-
ous reports indicated that these six proteins have important 
cellular functions, some of which could be related with pa-
thology. 
CPS1, normally found in hepatocytes and small-intestine 
(SI) enterocytes, is the rate-limiting enzyme that catalyzes 
the first step of the hepatic urea cycle. Deficiency in this 
enzyme results in an autosomal recessive disorder associ-
ated with hyperammonemia, protein intolerance, and im-
paired mental and physical development. The incidence of 
CPS I deficiency in Japan is 1:800000 [35]. Recently, re-
searchers found that expression of CPS1 in invasive 
small-intestine adenocarcinoma appears to be lost [36]. This 
could make this enzyme a diagnostically useful tool for 
identifying malignant tumors of the small-intestine.  
Dihydrolipoamide acetyltransferase (DLAT) is one of six 
components of the mammalian pyruvate dehydrogenase 
complex (PDC) of the inner mitochondrial membrane. Pa-
tients with primary biliary cirrhosis (PBC; 109720), have 
autoantibodies against DLAT. Pyruvate dehydrogenase de-
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ficiency is a major cause of primary lactic acidosis and 
neurological dysfunction in infancy and early childhood. 
Some researchers reported patients with pyruvate dehydro-
genase deficiency caused by defects in the E2 subunit. Epi-
sodic dystonia was the major neurological manifestation, 
with other more common features of pyruvate dehydro-
genase deficiency, such as hypotonia and ataxia, being less 
prominent. The patients had neuroradiological evidence of 
discrete lesions restricted to the globus pallidus [37]. 
The ALDH1A1 protein is quite abundant in mouse  
liver [38], suggesting that a major function for this enzyme 
could be removal of toxic substances. There is evidence that 
ALDH1A1 functions downstream of alcohol dehydrogenase 
(ADH1) in the oxidative clearance of excess retinol through 
metabolism to retinoic acid (RA). ALDH1A1 plays a do-     
minant role in the second stage of retinol clearance in adult 
mice. Vitamin A (retinol) is an essential nutrient for devel-
opmental regulation but is toxic in large amounts. A loss of 
ALDH1A1 results in accumulation of retinaldehyde pro-
duced by ADH1. Thus, ALDH1A1 may function to protect 
against alcohol or aldehyde toxicity in adults [39]. The en-
zyme is also highly expressed in non-small cell lung cancer 
and its downregulation is known to affect cell growth, cell 
motility and gene expression in lung cancer cells [40]. 
ALDH1A1 is also expressed at high levels in stem cells. 
Hematopoietic cells from Aldh1a1-deficient mice exhibit 
increased sensitivity to cyclophosphamide in a non-cell-     
autonomous manner, consistent with a role in cyclophos-
phamide metabolism in the liver [41]. ALDH1A1 is also as-
sociated with resistance to cyclophosphamide (CP) and its 
derivatives [42]. Interestingly, polymorphisms in ALDH1A1 
are correlated with an increased risk of liver toxicity [43]. 
ACAA2 is involved in β-oxidation of fatty acids. Fatty 
acids are important metabolic fuels, particularly at times of 
stress or fasting. They are predominantly metabolized in 
mitochondria, by a process requiring activation, transport 
into the mitochondria, and subsequent conversion to ace-
tyl-CoA by β-oxidation. This sequence of events may be 
impaired by genetic or environmental factors. A number of 
patients have been identified with defects in mitochondrial 
fatty acid oxidation. The clinical features in these patients 
include hypoketotic hypoglycemic coma, sudden infant 
death syndrome, Reye-like episodes, muscle weakness, and 
cardiomyopathy [44]. Researchers found ACAA2 could 
attenuate the apoptotic effects of BNIP3 in two human cell 
lines [45]. 
ECH1 is the second enzyme in the β-oxidation pathway. 
Down-regulation of ECH1 activity is correlated with resis-
tance of B-CLL (B-cell chronic lymphoid leukemia) cells to 
DNA damage-induced apoptosis. In this study, 13 genes were 
found to be specific for all resistant B-CLL cell samples, all 
of which were down-regulated, including ECH1 [46]. 
Hydroxysteroid (11-beta) dehydrogenase 1 (HSD11B1), 
plays an important role in regulating cortisol availability in 
target tissues. The enzyme is a primary regulator catalyz-
ing the reduction of inactive cortisone to active cortisol. 
Glucocorticoid excess promotes visceral obesity and car-
diovascular disease. Ligand availability to the glucocorti-
coid receptor is controlled by HSD11B, which also plays a 
crucial role in the pathogenesis of obesity and controls 
glucocorticoid action in inflammation. Expression of 
HSD11B1 was found to be significantly elevated in in-
flamed tissue compared to non-inflamed colon tissue [47]. 
Several studies have indicated that HSD11B1 plays a cru-
cial role in the onset of type 2 diabetes. Glucocorticoid 
action is linked to the development of obesity and insulin 
resistance. Recently, inhibition of HSD11B1 has been 
proposed as a strategy to suppress glucocorticoid action in 
a tissue-specific manner [48]. There is also preliminary 
evidence supporting an association of HSD11B1 with os-
teoporosis in postmenopausal women [49]. In this case, in-
creased HSD11B1 expression in fibroblasts could be a me-     
chanism for increasing local cortisol levels in membranes, 
which could potentiate the osteolytic process through inhi-
bition of osteoblastic function [50]. 
Studies on the induction of hepatic HSD11B1 in patients 
with alcoholic liver disease have shown mRNA expression 
of the enzyme was increased fivefold in the alcoholic liver 
disease (ALD) group compared with normal controls. These 
results show that significant induction of HSD11B1 gene 
expression and activity occurs in patients with ALD during 
short- and long-term abstinence from alcohol. The mecha-
nism underlying this is unknown, but might be explained on 
the basis of alcohol-induced changes in intracellular redox 
potential, or as a protective mechanism to limit liver in-
flammation and injury. Selective HSD11B1 inhibitors may 
offer a novel therapeutic approach to treat alcoholic 
pseudo-Cushing’s syndrome [51]. 
2.4  Subcellular localization of antibody-antigens com-
plexes 
To detect the antigens recognized by mAb localization in 
liver tissue, liver tissue slides were stained with selected 
mAbs and analyzed using fluorescence immunohistochem-
istry. The results showed that all mAbs had similar dotted 
staining patterns which localized in the cytoplasm (Figure 
4A). To demonstrate that the characteristic dotted staining 
was mitochondrial in origin, a double staining assay was 
performed. In these experiments, Rhodamine 123, (a green 
mitochondrial stain) and red TRITC conjugated goat 
anti-mouse IgG co-localized in the cytoplasm of the liver 
cells (Figure 4B, yellow). Hence, the mAbs generated in 
this study will provide useful tools as mitochondrial mark-
ers, and for labeling or isolating mitochondria.  
2.5  Depletion of antigenically dominant proteins from 
human liver mitochondrial proteins 
The successful purification and identification of low abun- 
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Figure 4  Immunohistochemistry staining of liver tissue samples was performed to analyze the distribution of the antigens recognized by selected mAbs in 
the liver tissue samples. Frozen sections were stained by mAb BAH103. A, mAb BAH103 recognition of brown particles within the cytoplasm of the liver 
cells. B, Double immunofluorescence staining was performed to determine whether mAb BAH103 and the mitochondria indicator Rhodamine 123 strain 
co-localize in the mitochondria. Mitochondria were visualized by staining a human liver carcinoma cell line (Huh7) with the mitochondria-specific marker 
Rhodamine 123 (green). The same slide was counter-stained with mAb BAH103 and TRITC labeled Goat anti-Mouse IgG as the second antibody (red) using  
indirect immunofluorescence. The merged section (yellow) shows mAb BAH103 and Rhodamine 123 co-localization within mitochondrial cells. 
dance proteins is currently a significant challenge in pro-
teomic research. Depletion of highly abundant proteins from 
proteomic samples is a commonly used strategy to enrich 
low abundance proteins. In the present study, native pro-
teins of unknown identity were used to immunize mice and 
generate mAbs that could be used to recognize native pro-
teins in human liver samples (as described in Materials and 
methods). As expected, antibodies against some proteins 
that were relatively abundant and immunodominant in the 
mixtures were generated. Antibody specificity was deter-
mined using an established antibody specificity identifica-
tion platform. The mAbs were found to be highly effective 
at depleting their cognate proteins from the liver samples. In 
these experiments, we used a new mAb designated BAH103, 
to deplete ECH1 from human liver mitochondria protein 
samples using immunoprecipitation (IP). No positive bands 
were observed in the BAH103 depleted liver lysates, as de-
termined by western blot analysis, indicating that ECH1 had 
been successfully depleted from the samples (Figure 5B). 
ECH1 depleted protein preparations were used to immunize 
mice. Western blots using the antiserum obtained revealed 
an absence of bands at positions corresponding to the mo-
lecular weight of ECH1 (Figure 5A and B). Other mAbs, 
such as BEH045, which was raised against CPS1 (one of 
the antigenically dominant proteins in liver mitochondria), 
were used to isolate enzymatic complexes from human liver 
mitochondria. These mAbs were also be used to deplete 
their corresponding antigen from human liver mitochondrial 
protein using IP [30]. These results provide strong impetus 
to generate mAbs against the less abundant or less immu-
nodominant proteins present in liver samples. This can be 
achieved using liver samples where the immunodominant 
proteins are first depleted. 
3  Conclusion 
In conclusion, monoclonal antibodies against highly abun-
dant or dominant liver mitochondrial proteins can be raised 
by immunizing mice with fractionated human liver mito-
chondrial proteins. Such mAbs have great potential to be- 
 
Figure 5  Depletion of antigenically dominant proteins from human liver 
mitochondria. A, Mitochondrial protein lysates were blotted with mAb 
BAH103 under the reduced condition and a positive band was observed. B, 
Protein lysates depleted by mAb BAH103 were blotted with mAb BAH103. 
No positive bands were observed. C, When the mitochondrial proteins 
were blotted with serum from a mouse immunized with BAH103 depleted 
protein preparation, no positive band at the position corresponding to 
BAH103 was observed. This result indicates that BAH103 was success- 
fully depleted from the mitochondria protein sample. 
come powerful tools for in vitro mitochondrial labeling or 
depletion of dominant proteins from liver samples.  
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